What is the target blood glucose range for adult intensive care unit (ICU) patients, including recommendations for non‑diabetic and diabetic individuals?

Target Blood Glucose Range for ICU Patients

For adult ICU patients, target a blood glucose range of 7.8–11.1 mmol/L (140–200 mg/dL), and initiate insulin therapy when blood glucose persistently exceeds 10 mmol/L (180 mg/dL). This applies to both diabetic and non-diabetic patients, with the primary goal being avoidance of hypoglycemia while preventing severe hyperglycemia 1.

Key Management Thresholds

Insulin Initiation

• Start insulin therapy when two consecutive blood glucose readings are ≥10 mmol/L (180 mg/dL) 1
• This trigger threshold is intentionally lower than the upper target limit to prevent prolonged hyperglycemia

Target Range During Treatment

• Maintain blood glucose between 7.8–11.1 mmol/L (140–200 mg/dL) 1
• This "conventional" range is strongly recommended over "intensive" control (4.4–7.7 mmol/L or 80–139 mg/dL)

Critical Evidence Against Tight Control

The 2024 Society of Critical Care Medicine guidelines explicitly recommend against intensive glucose control targeting 4.4–7.7 mmol/L (80–139 mg/dL) based on moderate-certainty evidence 1. This recommendation stems from:

• 3.6-fold increased risk of severe hypoglycemia with intensive targets 2
• Increased mortality demonstrated in the landmark NICE-SUGAR trial, where intensive control resulted in 27.5% mortality versus 24.9% with conventional control (OR 1.14, p=0.02) 3
• No mortality benefit from tight control in multiple meta-analyses 4, 2

Special Considerations for Diabetic Patients

The same target range (140–200 mg/dL) applies to patients with pre-existing diabetes 1, 5, 6. This is crucial because:

• Diabetic patients do not benefit from aggressive glucose reduction to the same extent as non-diabetic patients 6, 7
• They remain at risk for hypoglycemia but show less mortality benefit from tight control 7
• An upper limit of 10 mmol/L (180 mg/dL) is associated with better outcomes in diabetic patients than lower targets 6

Important caveat: Emerging observational data suggest potential benefit from personalized targets based on pre-hospital glycemic control (HbA1c), but this requires further study 1.

Implementation Strategy

Insulin Delivery

• Use continuous IV insulin infusion rather than subcutaneous insulin for acute hyperglycemia management 1
• This is a conditional recommendation with very low certainty, but IV infusion allows more precise titration

Monitoring Frequency

• Monitor glucose every ≤1 hour (or continuously) during periods of glycemic instability in patients on IV insulin 1
• Use protocols with explicit decision support tools to guide insulin titration 1

Hypoglycemia Prevention

• Treat hypoglycemia without delay 1
• Protocols must demonstrate low hypoglycemia risk before implementation
• Severe hypoglycemia (<2.2 mmol/L or 40 mg/dL) occurred in 6.8% with intensive control versus 0.5% with conventional control 3

Common Pitfalls to Avoid

1. Do not target normoglycemia (80–110 mg/dL) in ICU patients—this increases mortality 3, 4
2. Do not use the same aggressive targets for diabetic and non-diabetic patients—both groups should receive conventional control 1, 5, 6
3. Do not rely on inaccurate point-of-care devices without quality control—measurement accuracy is essential for safe glucose management 4
4. Do not ignore glucose variability—high variability (coefficient of variation ≥20%) is associated with increased mortality, particularly in non-diabetic patients 7

The Evidence Landscape

The shift from intensive to conventional glucose control represents a major reversal from earlier Leuven trials. The 2024 SCCM guidelines 1 synthesize evidence showing that while intensive control may reduce ICU length of stay and certain infections 2, the substantial hypoglycemia risk and lack of mortality benefit make conventional targets (140–200 mg/dL) the safer, evidence-based choice for the vast majority of ICU patients.